Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: Potent antiviral activity but no clinical benefit if treatment is given late
Adriano Pellicelli(Carlo Forlanini Hospital), M. Angélico, Christine M. Durand(Johns Hopkins University), Andrea Telese(University of Rome Tor Vergata), Ilaria Lenci, Stefan Zeuzem(Goethe University Frankfurt), Marzia Montalbano(Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani), Arnaldo Andreoli(Carlo Forlanini Hospital), Raffaella Lionetti(Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani), Viola Knop(University Hospital Frankfurt), Peter Ferenci(University of Vienna), Gianpiero D’Offizi(Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani)
Cited by 103
Related Papers
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
|New England Journal of Medicine|2002|3.3k
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2019|1.2k
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
|Gastroenterology|2016|1k
ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
|New England Journal of Medicine|2014|877